

4DMedical signs first US hospital SaaS contract

5 April 2023

Highlights

- 4DMedical signs US SaaS contract with the University of Miami
 - Five-year contract to deliver XV LVAS® scans, effective immediately
 - Follows success of long-term clinical trial program already underway at University of Miami
-

Melbourne, Australia, 5 April 2023: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces a significant milestone in its commercialisation journey with the signing of a five-year contract with the University of Miami to provide XV LVAS® (X-ray Velocimetry Lung Ventilation Analysis Software) ventilation reports.

Expanding on existing relationship

4DMedical has established a strong relationship with the University of Miami where joint clinical research is underway demonstrating the clinical value of XV Technology® across a range of indications, including Chronic Obstructive Pulmonary Disease (COPD). COPD represents a significant worldwide health problem, and according to the World Health Organisation (WHO) it is the third leading cause of death worldwide. The Australian Lung Foundation states that around 1 in 7 Australians over 40 have COPD, and around half of these don’t know that they have the condition. However, if diagnosed early enough (prior to the occurrence of structural changes in the lungs), COPD is a treatable condition.

Researchers at the University of Miami have presented findings from these trials at key international conferences, noting the clinical insights delivered using 4DMedical’s game changing technology. In addition, University of Miami researchers were integrally involved in the recently completed COPD study at Johns Hopkins. This study was initially presented in May 2022 at the American Thoracic Society conference. Key findings of the published study included that:

- XV Technology® derived metrics correspond with COPD disease severity;
- Pathophysiological insights have application in both clinical and research settings; and
- XV LVAS® scans visualise and quantify regional ventilation defects, which is critical to the optimisation of treatment therapies.

Contract framework

The agreement with the University of Miami sets out a framework for further expansion of 4DMedical’s XV Technology® into the US market. Under the terms of the contract, 4DMedical will deploy XV Technology® at the University of Miami, enabling patient data to be processed on demand.

Importantly, this agreement includes minimum annual fees and represents a significant milestone in the commercialisation strategy of the Company in the US, validating the efficacy and utility of XV Technology®.

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 102
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



University of Miami Chief of Pulmonary and Sleep Medicine, Professor Naresh Punjabi, said:

We have had a long-standing relationship with the team at 4DMedical. Over that time, we have gained invaluable expertise in applying XV Technology® across various use cases and patient populations. We believe XV Technology® holds enormous potential to enhance clinical outcomes. I'm thrilled to be at the forefront of this ground-breaking technology and believe that XV LVAS® has the potential to revolutionize the way we diagnose and manage respiratory conditions.

4DMedical MD/CEO and Founder Andreas Fouras said:

Today's announcement of our first US SaaS contract reflects the attainment of a key milestone in the Company's commercialisation journey. Furthermore, the fact this milestone was completed with our clinical trial partners at the University of Miami, who have developed such an extensive understanding of XV Technology®, is especially satisfying.

The Company continues to go from strength to strength as commercialisation accelerates. I am excited by recent progress both in Australia and the USA, and I look forward to providing further positive updates over the coming weeks and months.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

CFO

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Melanie Leydin

companysecretary@4dmedical.com

Media Enquiries

TCN

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared X-ray Velocimetry Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit www.4dmedical.com.